ANNALS OF ONCOLOGY, cilt.26, ss.245, 2015 (SCI İndekslerine Giren Dergi)
This letter criticize the design of ACTS-CC trial; patients received adjuvant oral fluoropyrimidine therapy without oxaliplatin. Authors believe that oxaplatin should have been a part of the treatment in both arms.